Section Arrow
LTRN.NASDAQ
- Lantern Pharma
Quotes are at least 15-min delayed:2025/07/21 18:51 EDT
After Hours
Last
 3.8
+0.01 (+0.26%)
Bid
3.57
Ask
3.8
High 3.8 
Low 3.77 
Volume 1757 
Regular Hours
Last
 3.79
-0.2 (-5.01%)
Day High 
3.98 
Prev. Close
3.99 
1-M High
4.4679 
Volume 
453.13K 
Bid
3.57
Ask
3.8
Day Low
3.55 
Open
3.87 
1-M Low
3.0111 
Market Cap 
43.03M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.73 
20-SMA 3.45 
50-SMA 3.44 
52-W High 6.118 
52-W Low 2.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.84/-1.14
Enterprise Value
43.08M
Balance Sheet
Book Value Per Share
1.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
After Hours 0.1188 -0.0106 -8.19%
NCNANuCana plc0.051+0.0033+6.92%-- 
After Hours 0.0563 +0.0053 +10.39%
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
After Hours 1.07 -0.05 -4.46%
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
After Hours 2.67 -0.03 -1.11%
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
After Hours 6.43 +0.03 +0.47%
Quotes are at least 15-min delayed:2025/07/21 18:51 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.